Katherine Bowdish, Ph.D. is Vice President Global R&D, and Head of Sanofi’s Sunrise Ventures. Kathy joined Sanofi in 2013 to build and lead Sunrise. Sunrise co-creates and invests in companies advancing early-stage cutting-edge science, simultaneously serving as an investor and first partner to accelerate transformative treatments to patients. Kathy brings extensive experience in the life science industry as a scientist, entrepreneur and leader. After completing her Ph.D. in molecular genetics from Columbia University, College of Physicians and Surgeons, and post-doctoral work at UCLA, she co-founded and launched her first biotechnology company with a focus on antibody therapies. Following its acquisition, she continued down the entrepreneurial path leading two additional biologics-focused companies. Past positions included President & CSO, Permeon Biologics; Co-founder, President & CEO, Anaphore; President, Alexion Antibody Technologies and Senior Vice President, Alexion Pharmaceuticals; and Founder, CEO & CSO, Prolifaron prior to its acquisition by Alexion. In her current role, Katherine supports and nurtures entrepreneurial science through early-stage investments, and by serving on the Boards of Directors of several biotechnology companies.